Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present FluoroPharma Medical, Inc. (OTC: FPMI).

Full DD Report for FPMI

You must become a subscriber to view this report.



Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-12N/A0.095N/AN/A0
2018-12-11N/A0.095N/AN/A0
2018-12-10N/A0.095N/AN/A0
2018-12-070.0950.0950.0950.0956,045
2018-12-060.0950.06120.0950.061211,040

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-041,00013,4127.4560Cover
2018-12-031,00081,0001.2346Cover
2018-11-305,00027,10518.4468Cover
2018-11-2720,00050,00040.0000Short
2018-11-128,00011,00072.7273Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on FPMI.


About FluoroPharma Medical, Inc. (OTC: FPMI)

Logo for FluoroPharma Medical, Inc. (OTC: FPMI)

We are a molecular imaging company headquartered in Montclair, NJ. The Company was founded to engage in the discovery, development and commercialization of proprietary products for the positron emission tomography PET market. The Company s initial focus has been on the development of novel cardiovascular imaging agents that can more efficiently and effectively detect and assess acute and chronic forms of coronary artery disease CAD . Molecular imaging pharmaceuticals are radiopharmaceuticals that enable early detection of disease through the visualization of subtle changes in biochemical and biological processes.

 

Contact Information

 

 

Current Management

  • Dr. Thomas H. Tulip / President
    • On October , , the Company entered into a threeyear employment agreement with Dr. Tulip to join the Company as President. Dr. Tulip served in leadership roles at Navidea BioPharmaceuticals, Inc. from . He spent more than years in the development and commercialization of radiopharmaceuticals and imaging agents, with a track record of success in R amp D, business development, brand and alliance management as well as international business. Prior to his tenure at Navidea Biopharmaceuticals, Dr. Tulip held senior leadership positions at Alseres Pharmaceuticals, Lantheus Medical Imaging LMI , Bristol Myers Squibb BMS and DuPont, where his roles spanned product discovery and development, business and technology planning, brand and alliance management and international business management. He served as President of Alseres Molecular Imaging where he led efforts to develop markets for a Phase III neuroimaging agent. While at BMS and DuPont , he was instrumental in the development, commercialization and international management of the highly successful nuclear cardiology franchise, successfully built the BMS Medical Imaging international business, and led planning activities for innovative PET tracers at LMI/BMS. He was Treasurer and Board Member of the Academy of Molecular Imaging and Chairperson of its Institute for Molecular Technologies IMT , where he held numerous leadership positions. Dr. Tulip was Chairperson of the Society of Nuclear Medicine SNM Corporate Advisory Board. He serves on the Board of Directors of the Medical Imaging Technology Association MITA and leads its PET Working Group in the Molecular Imaging Section. He has served as a Director of Council on Radionuclides and Radiopharmaceuticals CORAR . He earned a B.S. from the University of Vermont, and an M.S. and Ph.D. from the Northwestern University.
  • Tamara Rhein / CFO
    • Tamara Rhein has been our chief financial officer since August , and served as our financial controller since July . From November until joining us, Ms. Rhein was controller for Manhattan Pharmaceuticals, where she was responsible for a wide range of activities, including financial statement preparation, footnote disclosures for SEC filings, stock option accounting and quarterly and yearend audits. From until , Ms. Rhein was with Vyteris, where her primary role was to manage the SEC accounting and reporting department. Ms. Rhein received a Bachelor s of Science degree in accounting from California State University at Northridge and is also a certified public accountant.
  • Lawrence Atinsky / Director
    • Lawrence Atinsky has been a member of our Board January , . During the past seven years, Mr. Atinsky has been a partner at Ascent Biomedical Ventures, or ABV, a venture capital firm investing in seed and earlystage biomedical technology companies developing medical devices, biopharmaceuticals, healthcare services, and information technology. Prior to joining ABV, Mr. Atinsky was a corporate attorney at Skadden, Arps, Slate, Meagher amp Flom in New York, where he was involved in structuring and negotiating numerous private and public merger and acquisition transactions. Mr. Atinsky has also been the General Counsel of several private companies in the healthcare industry and has been a founder and investor in earlystage medical technology companies. Mr. Atinsky earned a J.D. from New York University School of Law and B.A. degrees in Political Science and Philosophy from the University of WisconsinMadison. We believe that Mr. Atinsky s experience as a corporate attorney and background in venture capital focusing on biomedical technology companies enable him to provide a valuable perspective to our Board.
  • Peter S. Conti / Director
    • Peter S. Conti, M.D., Ph.D. has been a member of our Board since February , . Dr. Conti is a tenured Professor of Radiology, Pharmacy and Biomedical Engineering at the University of Southern California, as well as Director of the USC Positron Imaging Science Center and Clinic since its inception in . He is also the Director of the Molecular Imaging Laboratory at USC. Dr. Conti received his medical and doctoral degrees from Cornell University, and completed his residency in Diagnostic Radiology and Fellowship in Nuclear Medicine at The Johns Hopkins Medical Institutions. Dr. Conti is Board Certified in both Diagnostic Radiology and Nuclear Medicine. He is a Fellow of the American College of Radiology and of the American College of Nuclear Medicine Physicians. Dr. Conti is a past President of the Society of Nuclear Medicine SNM , and continues to serve on a number of committees for the Society, including those involving government and regulatory affairs related to the development of Molecular Imaging technology and its applications in medicine. We believe that Dr. Conti s broad range of experience in medicine, academia, and administration enable him to provide a unique and valuable perspective to our Board.
  • Austin Lewis / Director
    • W. Austin Lewis, IV, age , currently serves as CEO, CFO, and a Director of PAID, Inc., a company focusing on webdevelopment and online auctions, as well as the CEO of Lewis Asset Management Corp., an investment management company headquartered in New York City, which he founded in . From to , Mr. Lewis was employed at Puglisi amp Company, a New York based brokerdealer registered with FINRA, where he served as a registered representative and managed individual client accounts, conducted due diligence for investment banking activities and managed his own personal account. In , Mr. Lewis cofounded Thompson Davis amp Company, Inc., a registered brokerdealer headquartered in Richmond, Virginia. Mr. Lewis received his Bachelor of Science degree in Finance and Financial Economics from James Madison University in . Mr. Lewis is a also a director on the following companies with a class of securities registered: MAM Software Group, Inc., Quest Solutions and ScripsAmerica, Inc. Lewis Opportunity Fund, an affiliate of Mr. Lewis, participated as an investor in the Company s recent private placement and was issued convertible promissory notes in an aggregate principal amount of , , and warrants to purchase an aggregate of , , shares of common stock. The Board believes that Mr. Lewis s management and financial industry experience, together with his understanding of the Company s business, provides him with the appropriate skills to serve as a member of the Board.
  • Johan M. Spoor / Director
    • Johan M. Thijs Spoor has been our president, chief executive officer and a member of our Board since February , , and has been the Chairman of our Board since June , . Mr. Spoor was the chief financial officer for Sunstone BioSciences from February through September . From December until joining Sunstone BioSciences, he worked at Oliver Wyman as a consultant to pharmaceutical and medical device companies. Mr. Spoor was an equity research analyst at J.P. Morgan from July through October and at Credit Suisse from November through July , covering the biotechnology and medical device industries. Prior to his career on Wall Street, Mr. Spoor worked in the pharmaceutical industry spending years with Amersham / GE Healthcare where he worked in countries in a variety of roles including setting up GMP facilities, accountability for the nuclear cardiology portfolio and most recently as the Director of New Product Opportunities leading the PET strategic plan. Mr. Spoor also sits on the board of directors of MetaStat, Inc. MTST , AtheroNova, Inc. AHRO and Protea Biosciences Group, Inc. He holds a Nuclear Pharmacy degree from the University of Toronto as well as an M.B.A. from Columbia University. We believe that Mr. Spoor s background in nuclear pharmacy, finance and accounting and as a healthcare research analyst, as well as his experience at both large and small healthcare companies, provides him with a broad familiarity of the range of issues confronting our company, which makes him a qualified member of our Board.
  • Dr. Thomas H. Tulip / Director
    • On October , , the Company entered into a threeyear employment agreement with Dr. Tulip to join the Company as President. Dr. Tulip served in leadership roles at Navidea BioPharmaceuticals, Inc. from . He spent more than years in the development and commercialization of radiopharmaceuticals and imaging agents, with a track record of success in R amp D, business development, brand and alliance management as well as international business. Prior to his tenure at Navidea Biopharmaceuticals, Dr. Tulip held senior leadership positions at Alseres Pharmaceuticals, Lantheus Medical Imaging LMI , Bristol Myers Squibb BMS and DuPont, where his roles spanned product discovery and development, business and technology planning, brand and alliance management and international business management. He served as President of Alseres Molecular Imaging where he led efforts to develop markets for a Phase III neuroimaging agent. While at BMS and DuPont , he was instrumental in the development, commercialization and international management of the highly successful nuclear cardiology franchise, successfully built the BMS Medical Imaging international business, and led planning activities for innovative PET tracers at LMI/BMS. He was Treasurer and Board Member of the Academy of Molecular Imaging and Chairperson of its Institute for Molecular Technologies IMT , where he held numerous leadership positions. Dr. Tulip was Chairperson of the Society of Nuclear Medicine SNM Corporate Advisory Board. He serves on the Board of Directors of the Medical Imaging Technology Association MITA and leads its PET Working Group in the Molecular Imaging Section. He has served as a Director of Council on Radionuclides and Radiopharmaceuticals CORAR . He earned a B.S. from the University of Vermont, and an M.S. and Ph.D. from the Northwestern University.
  • Walter Witoshkin / Director
    • Walter Witoshkin has been a member of our Board since February , . Mr. Witoshkin was the chairman and chief executive officer of QuantRx Biomedical Corporation, a medical technology company from April through August . Mr. Witoshkin has held executive positions in the healthcare and pharmaceutical industries including senior financial positions at Wyeth Labs American Cyanimade , VP Business Development and chief financial officer positions at SmithKline Beecham now Glaxo SmithKline and Menley amp James Laboratories, Inc. He is a founding partner of the Trident Group, a global consultancy to the pharmaceutical industry. We believe that Mr. Witoshkin s industry specific extensive management experience provides him with a broad and deep understanding of our business and our competitors efforts, which is an invaluable resource to our Board.

Current Share Structure

  • Market Cap: $3,621,545 - 03/16/2018
  • Authorized: 200,000,000 - 03/01/2018
  • Issue and Outstanding: 34,490,907 - 03/01/2018
  • Float: 21,756,232 - 04/12/2016

 



Daily Technical Chart for (OTC: FPMI)

Daily Technical Chart for (OTC: FPMI)


Stay tuned for daily updates and more on (OTC: FPMI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: FPMI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in FPMI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of FPMI and does not buy, sell, or trade any shares of FPMI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/